Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.

Expert opinion on investigational drugs - 1 Mar 2011

Antoniu Sabina Antonela

Abstract excerpt

INTRODUCTION: Several types of mutations in the cystic fibrosis transmembrane regulator (CFTR) gene lead to abnormal CFTR protein and alterations of chloride and sodium transmembrane transportation in cystic fibrosis (CF). Some investigational compounds such as VX-770 can improve CFTR protein function. AREAS COVERED: This paper discusses the results of a Phase II study investigating the safety and efficacy of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Aminophenols
Share to Cell Membrane

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Double-Blind Method

Share to Ion Transport

Share to Quinolones

Source

Identifiers

PMID: 21303308
DOI: 10.1517/13543784.2011.554823

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.PMID 21303308Read ↗

Cystic Fibrosis Transmembrane Conductance Regulator–Modifying Medications: The Future of Cystic Fibrosis TreatmentSemantic proximity Read ↗

Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.Semantic proximity Read ↗

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.Semantic proximity Read ↗

Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors.Semantic proximity Read ↗

Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosisSemantic proximity Read ↗

New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.Semantic proximity Read ↗

Cystic fibrosis transmembrane conductance regulator modulators: the end of the beginning.Semantic proximity Read ↗

Targeted therapy for cystic fibrosisSemantic proximity Read ↗

Discovery of CFTR modulators for the treatment of cystic fibrosis.Semantic proximity Read ↗

Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251).Semantic proximity Read ↗

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.Semantic proximity Read ↗

Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.